The present invention relates to a needle-free injector using pulsed shock waves, the needle-free injector comprising: a power unit generating pulsed power; a pulsed shock wave generating unit which receives the pulsed power and generates pulsed shock waves; an upper housing in which a liquid and the pulsed shock wave generating unit are disposed; a lower housing which is connected to the upper housing, and in which a drug is disposed; a shock wave transmission unit which is provided between the upper housing and the lower housing to separate the upper housing and the lower housing; and an injection unit which is disposed in the lower housing and inject the drug.

A bioelectronic device houses therapeutic cells and is configured to be implanted in a host. The device includes an electrochemical cell that produces oxygen gas from water when a voltage is applied. The oxygen gas produced by the electrochemical cell is stored in a gas diffusion chamber in the device. The therapeutic cells in a cell housing chamber in the device receive oxygen gas from the gas diffusion chamber to help keep the cells alive and functioning when the device is implanted in a low oxygen environment. The device receives power wirelessly.

A bioelectronic device houses therapeutic cells and is configured to be implanted in a host. The device includes an electrochemical cell that produces oxygen gas from water when a voltage is applied. The oxygen gas produced by the electrochemical cell is stored in a gas diffusion chamber in the device. The therapeutic cells in a cell housing chamber in the device receive oxygen gas from the gas diffusion chamber to help keep the cells alive and functioning when the device is implanted in a low oxygen environment. The device receives power wirelessly.

A craniofacial implant includes a mounting plate, a low profile intercranial device including a static cranial implant and a functional neurosurgical implant, and an ultrasound transducer.

Self-righting articles, such as self-righting capsules for administration to a subject, are generally provided. In some embodiments, the self-righting article may be configured such that the article may orient itself relative to a surface. In some embodiments, the self-righting article may have a particular shape and/or distribution of density (or mass) which, for example, enables the self-righting behavior of the article. In some embodiments, the self-righting article may comprise a tissue interfacing component and/or a pharmaceutical agent. In some cases, upon contact of the tissue with the tissue engaging surface of the article, the self-righting article may be configured to release one or more tissue interfacing components. In some cases, the tissue interfacing component may comprise and/or be associated with the pharmaceutical agent.

Chimeric antigen receptor T cells (CAR T) therapy reached a milestone in eradicating B-cell malignancies, but beneficial effects in solid tumors are not obtained yet. A porous microneedle patch is disclosed that carries CAR T cells to solid tumors (or other cell types). The device is a honeycomb-like porous microneedle patch that accommodates CAR T cells and allows in situ penetration-media seeding of CAR T cells within post-surgical resection of solid tumors. CAR T cells loaded in the pores of the microneedle tips were readily escorted to the tumor in an evenly scattered manner without losing their activity. Such microneedle-mediated local delivery enhanced infiltration and immune stimulation of CAR T cells as compared to direct intratumoral injection. This tailorable patch offers a transformative platform for scattered seeding of living cells for treating a variety of diseases. Other cell types may be loaded into the porous microneedles.

Disclosed herein are compositions and in vitro and in vivo methods for reprogramming post-natal (adult and juvenile) tissue into insulinogenic cells. These compositions and methods are useful for a variety of purposes, including the development of diabetes therapies.

Disclosed are a particle-attached microneedle having a solid-phase drug mounted thereon, and a method of manufacturing the particle-attached microneedle. More particularly, the particle-attached microneedle includes a microneedle (10), an adhesive layer (11), solid-phase drug particles (22), a film (21), and a coating well (20).

The present disclosure relates to microneedle devices and methods for treating a disease (for example, diabetes) using a degradable cross-linked gel for self-regulated delivery of a therapeutic agent (for example, insulin).

A microneedle assembly and a method of fabrication the assembly are provided. The microneedle assembly includes an array of microneedles attached to a base. Each of the microneedles comprise a tip, a needle shaft and a plurality of cantilevered barbs protruding outwardly from the needle shaft, where a plurality of the microneedles include two or more of the cantilevered barbs arranged in a series of concentric rings along the needle shaft of each of the plurality of microneedles. The microneedle assembly may be fabricated using a 3D printing technique, where one or more cantilevered layers are formed by exposing a photocurable liquid resin including monomer material to a light source to create initially horizontal, cantilevered barbs having a crosslinking gradient, and rinsing to remove an amount of un-crosslinked monomers from the cantilevered layers to induce curvature in the cantilevered barbs extending towards a direction of the lower crosslinking.